Issues in the Management of Challenging Behaviours of Adults with Autism Spectrum Disorder

Autism spectrum disorder (ASD) is a particularly important risk factor for challenging behaviours such as aggression, tantrums, self-injury and pica. Adults with ASD have rarely been studied with respect to these problems. This is particularly disconcerting since there are far more adults than children with ASD. In addition, because of adults’ increased physical size and longer history of these problems, treating these behaviours effectively is important.Psychological methods, particularly applied behaviour analysis, and pharmacotherapy have been the most frequently addressed treatments for challenging behaviours associated with ASD in the research literature. In many cases, challenging behaviours have clear environmental antecedents. In these cases, behavioural interventions, such as applied behaviour analysis, should be used to reduce the behaviours. When environmental factors cannot be identified or when challenging behaviours are very severe, pharmacological treatments may be necessary in combination with behavioural interventions. Newer antipsychotics are the most researched medications for use with this population. Currently, risperidone and aripiprazole are the only medications that have US FDA approval for the treatment of behaviours associated with ASD, specifically irritability; however, they are indicated for use in children not adults. It is important not to use medications unnecessarily, due to possible side effects associated with their use.Based on available research, some recommendations for the treatment of challenging behaviours of adults (and children) with ASD include the use of functional assessment, side-effect monitoring of medications and behavioural methods whenever possible. Additionally, future research in this area needs to focus more on adults, as most current research has used child samples.

[1]  A. Wolverton,et al.  Autism spectrum disorder grown up: a chart review of adult functioning. , 2009, Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent.

[2]  J. Matson,et al.  A validity study on the Questions About Behavioral Function (QABF) Scale: predicting treatment success for self-injury, aggression, and stereotypies. , 1999, Research in developmental disabilities.

[3]  E. Hollander,et al.  Targeted treatments for symptom domains in child and adolescent autism , 2003, The Lancet.

[4]  J. Matson,et al.  An Examination of Psychotropic Medication Side Effects: does taking a greater number of psychotropic medications from different classes affect presentation of side effects in adults with ID? , 2010, Research in developmental disabilities.

[5]  C. McDougle,et al.  Case series: use of ziprasidone for maladaptive symptoms in youths with autism. , 2002, Journal of the American Academy of Child and Adolescent Psychiatry.

[6]  J. Hellings,et al.  Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. , 2001, Journal of child and adolescent psychopharmacology.

[7]  J. Matson Determining treatment outcome in early intervention programs for autism spectrum disorders: a critical analysis of measurement issues in learning based interventions. , 2007, Research in developmental disabilities.

[8]  F. Volkmar,et al.  Social Skills Interventions for Individuals with Autism: Evaluation for Evidence-Based Practices within a Best Evidence Synthesis Framework , 2010, Journal of autism and developmental disorders.

[9]  O. Healy,et al.  Long-term post-intensive behavioral intervention outcomes for five children with Autism Spectrum Disorder , 2010 .

[10]  C. McDougle,et al.  Risperidone in Adults with Autism or Pervasive Developmental Disorder , 1995 .

[11]  Janet E. Graetz Autism grows up: opportunities for adults with autism , 2010 .

[12]  B. Iwata,et al.  Behavior analysis in intellectual and developmental disabilities. , 2010 .

[13]  J. Matson,et al.  Progression of challenging behaviors in children and adolescents with Autism Spectrum Disorders as measured by the Autism Spectrum Disorders-Problem Behaviors for Children (ASD-PBC) , 2010 .

[14]  G. Maislin,et al.  Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. , 2002, Journal of the American Academy of Child and Adolescent Psychiatry.

[15]  C. McDougle,et al.  Pharmacotherapy of irritability in pervasive developmental disorders. , 2008, Child and adolescent psychiatric clinics of North America.

[16]  Johnny L. Matson,et al.  Applied Behavior Analysis for Children with Autism Spectrum Disorders , 2009 .

[17]  J. Gurney,et al.  National Autism Prevalence Trends From United States Special Education Data , 2005, Pediatrics.

[18]  J. Virués-Ortega,et al.  Applied behavior analytic intervention for autism in early childhood: meta-analysis, meta-regression and dose-response meta-analysis of multiple outcomes. , 2010, Clinical psychology review.

[19]  C. McDougle,et al.  Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. , 2003, Journal of the American Academy of Child and Adolescent Psychiatry.

[20]  J. Carr The handbook of intellectual disability and clinical psychology practice , 2009 .

[21]  R. Mcquade,et al.  A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. , 2009, Journal of the American Academy of Child and Adolescent Psychiatry.

[22]  E. Dehon,et al.  Psychopharmacology of aggression in children and adolescents with primary neuropsychiatric disorders: a review of current and potentially promising treatment options. , 2010, Experimental and clinical psychopharmacology.

[23]  C. McDougle,et al.  Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. , 1999, Journal of clinical psychopharmacology.

[24]  B. Leventhal,et al.  Fluoxetine treatment of children and adults with autistic disorder and mental retardation. , 1992, Journal of the American Academy of Child and Adolescent Psychiatry.

[25]  L. Koegel,et al.  Pivotal Areas in Intervention for Autism , 2001, Journal of clinical child psychology.

[26]  B. Iwata,et al.  Toward a functional analysis of self-injury. , 1994, Journal of applied behavior analysis.

[27]  J. P. Gitlesen,et al.  Psychotropic medication in adults with mental retardation: prevalence, and prescription practices. , 2004, Research in developmental disabilities.

[28]  P. Sturmey,et al.  Assessment of Challenging Behaviors in People with Autism Spectrum Disorders , 2008 .

[29]  G. Remington,et al.  Clomipramine Versus Haloperidol in the Treatment of Autistic Disorder: A Double-Blind, Placebo-Controlled, Crossover Study , 2001, Journal of clinical psychopharmacology.

[30]  C. McDougle,et al.  Pharmacology of autism , 2006, Clinical Neuroscience Research.

[31]  D. Murphy,et al.  Aggressive Behaviour in Adults with Intellectual Disability , 2009, CNS drugs.

[32]  M. Huff,et al.  Clinical management of adolescents with autism. , 2008, Pediatric clinics of North America.

[33]  E. Kravariti,et al.  Challenging behavior and co-morbid psychopathology in adults with intellectual disability and autism spectrum disorders. , 2010, Research in developmental disabilities.

[34]  J. Matson Aggression and Tantrums in Children with Autism: A Review of Behavioral Treatments and Maintaining Variables , 2009 .

[35]  M. Aman,et al.  Psychotropic and anticonvulsant drugs in subjects with autism: prevalence and patterns of use. , 1995, Journal of the American Academy of Child and Adolescent Psychiatry.

[36]  Jin-Ding Lin,et al.  Administrative Prevalence of autism spectrum disorders based on national disability registers in Taiwan , 2009 .

[37]  B. Benson,et al.  Changes in Restricted Repetitive Behaviors with age: A study of high-functioning adults with Autism Spectrum Disorders , 2010 .

[38]  Robert H. Horner,et al.  Problem Behavior Interventions for Young Children with Autism: A Research Synthesis , 2002, Journal of autism and developmental disorders.

[39]  L. Lee,et al.  Increased risk of injury in children with developmental disabilities. , 2008, Research in developmental disabilities.

[40]  J. Sigafoos Communication Development and Aberrant Behavior in Children with Developmental Disabilities , 2000 .

[41]  B. Handen,et al.  Pharmacotherapy in Autism and Related Disorders. , 2005 .

[42]  D. Zachor,et al.  The effects of intellectual functioning and autism severity on outcome of early behavioral intervention for children with autism. , 2007, Research in developmental disabilities.

[43]  P. Sturmey,et al.  Correlates of restraint use in an institutional population: a replication. , 2005, Journal of intellectual disability research : JIDR.

[44]  S. Hall,et al.  Risk markers associated with challenging behaviours in people with intellectual disabilities: a meta-analytic study. , 2003, Journal of intellectual disability research : JIDR.

[45]  J. Matson,et al.  Trends and topics in autism spectrum disorders research , 2009 .

[46]  Jonathan M. Campbell,et al.  Efficacy of behavioral interventions for reducing problem behavior in persons with autism: a quantitative synthesis of single-subject research. , 2003, Research in developmental disabilities.

[47]  C. McDougle,et al.  Developing drugs for core social and communication impairment in autism. , 2008, Child and adolescent psychiatric clinics of North America.

[48]  Soyeon Kang,et al.  Behavioral treatment of chronic skin-picking in individuals with developmental disabilities: a systematic review. , 2010, Research in developmental disabilities.

[49]  L. Soorya,et al.  Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. , 2005, The international journal of neuropsychopharmacology.

[50]  Julee Waldrop,et al.  Pharmacologic treatment for the core deficits and associated symptoms of autism in children. , 2009, Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners.

[51]  R. Canitano,et al.  Psychopharmacology in autism: An update , 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[52]  S. Potkin,et al.  A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization , 2006, Schizophrenia Research.

[53]  C. McDougle,et al.  A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. , 1998, Archives of general psychiatry.

[54]  J. Matson,et al.  The convergent and divergent validity of the Matson Evaluation of Drug Side-effects (MEDS) and the Dyskinesia Identification System: Condensed User Scale (DISCUS) , 2008, Journal of intellectual & developmental disability.

[55]  Jonathan M. Campbell,et al.  Comparing Functional Assessment Methodologies: A Quantitative Synthesis , 2007, Journal of autism and developmental disorders.

[56]  L. Eaves,et al.  Young Adult Outcome of Autism Spectrum Disorders , 2008, Journal of autism and developmental disorders.

[57]  C. Advokat,et al.  Side effect profiles of atypical antipsychotics, typical antipsychotics, or no psychotropic medications in persons with mental retardation. , 2000, Research in developmental disabilities.

[58]  E. Emerson,et al.  The prevalence of challenging behaviors: a total population study. , 2001, Research in developmental disabilities.

[59]  F. Volkmar,et al.  Higher-functioning pervasive developmental disorders: rates and patterns of psychotropic drug use. , 1999, Journal of the American Academy of Child and Adolescent Psychiatry.

[60]  Kristal E. Ehrhardt,et al.  Conspicuous by the their absence: Studies comparing and combining risperidone and applied behavior analysis to reduce challenging behavior in children with autism , 2009 .

[61]  E. Emerson,et al.  The form and function of challenging behaviours. , 1995, Journal of intellectual disability research : JIDR.

[62]  M. Aman,et al.  The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. , 1985, American journal of mental deficiency.

[63]  P. Bolton,et al.  Episodic psychiatric disorders in teenagers with learning disabilities with and without autism , 2006, British Journal of Psychiatry.